Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Apr 20;15(5):503.
doi: 10.3390/ph15050503.

Drug Candidates for Autoimmune Diseases

Sabrina Saurin  1   2 , Myriam Meineck  1   2 , Gerhard Erkel  3 , Till Opatz  4 , Julia Weinmann-Menke  1   2 , Andrea Pautz  5
Affiliations
Review

Drug Candidates for Autoimmune Diseases

Sabrina Saurin et al. Pharmaceuticals (Basel). .

Abstract

Most of the immunosuppressive drugs used in the clinic to prevent organ rejection or to treat autoimmune disorders were originally isolated from fungi or bacteria. Therefore, in addition to plants, these are valuable sources for identification of new potent drugs. Many side effects of established drugs limit their usage and make the identification of new immunosuppressants necessary. In this review, we present a comprehensive overview of natural products with potent anti-inflammatory activities that have been tested successfully in different models of chronic inflammatory autoimmune diseases. Some of these candidates already have passed first clinical trials. The anti-inflammatory potency of these natural products was often comparable to those of established drugs, and they could be used at least in addition to standard therapy to reduce their dose to minimize unwanted side effects. A frequent mode of action is the inhibition of classical inflammatory signaling pathways, such as NF-κB, in combination with downregulation of oxidative stress. A drawback for the therapeutic use of those natural products is their moderate bioavailability, which can be optimized by chemical modifications and, in addition, further safety studies are necessary. Altogether, very interesting candidate compounds exist which have the potential to serve as starting points for the development of new immunosuppressive drugs.

Keywords: autoimmunity; inflammation; macrolactone; natural products.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Similar articles

See all similar articles

Cited by

References

    1. Ngo S.T., Steyn F.J., McCombe P.A. Gender differences in autoimmune disease. Front. Neuroendocrinol. 2014;35:347–369. doi: 10.1016/j.yfrne.2014.04.004. - DOI - PubMed
    1. Stojanovich L., Marisavljevich D. Stress as a trigger of autoimmune disease. Autoimmun. Rev. 2008;7:209–213. doi: 10.1016/j.autrev.2007.11.007. - DOI - PubMed
    1. Furie R., Rovin B.H., Houssiau F., Malvar A., Teng Y.K.O., Contreras G., Amoura Z., Yu X., Mok C.C., Santiago M.B., et al. Two-year, randomized, controlled trial of belimumab in lupus nephritis. N. Engl. J. Med. 2020;383:1117–1128. doi: 10.1056/NEJMoa2001180. - DOI - PubMed
    1. Furie R., Petri M., Zamani O., Cervera R., Wallace D.J., Tegzova D., Sanchez-Guerrero J., Schwarting A., Merrill J.T., Chatham W.W., et al. A phase iii, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits b lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum. 2011;63:3918–3930. doi: 10.1002/art.30613. - DOI - PMC - PubMed
    1. Jang D.I., Lee A.H., Shin H.Y., Song H.R., Park J.H., Kang T.B., Lee S.R., Yang S.H. The role of tumor necrosis factor alpha (tnf-alpha) in autoimmune disease and current tnf-alpha inhibitors in therapeutics. Int. J. Mol. Sci. 2021;22:2719. doi: 10.3390/ijms22052719. - DOI - PMC - PubMed

LinkOut - more resources